Date: Oct. 8, 2020
Source: Office of Scientific Research and Development
Author: Xie Chao

Jinan University has been approved as the Base for Commercialization of Scientific and Research Findings and Technology Transfer, according to a notice from the General Office of the Ministry of Education. This is another important achievement of the platform and environment construction of commercialization of scientific and research findings. JNU was previously approved as one of Guangdong’s first pilot universities for Technology Shareholding Reform in Operational Fields and as the Patent Technology Transfer and Transformation Center of Guangzhou universities.

Qualifying such bases is an important measure of the Ministry of Education to promote strategic action by colleges and universities serving the country, and to form universities' and colleges' commercialization systems with their own characteristics. A total of 77 colleges and universities applied for the base qualification this time, and after letter evaluations and defense evaluations, 24 universities were approved.
 

In recent years, JNU has adhered to the orientation to do the most cutting-edge research, to yield the most pragmatic results. The school serves urgent needs of national and regional innovation with the construction of new research-and-development institutions. It advances key technological achievements by deepening the integration of production and education. It also builds a full-chain and all-round commercialization model — business management + market operation — through deepening the reform of the commercialization mechanism.

Since 2017, the school has completed the implementation of intellectual property standards; set up a venture capital fund for commercialization of technological achievements; and established 10 local research institutes and independent R&D institutions, 5 of which have qualified as Guangdong New-Type R&D Institution. It has completed the transfers of 76 patent achievements and the promotion of hundreds of technological applications, with contract values exceeding 2 billion yuan, and serving nearly 500 companies and research institutions, including Huawei, Gree, Livzon, China General Nuclear Power, Infinitus and Perfect. It has transformed several major new drugs in the pharmacy field, a national double first-class discipline of JNU. Among them, the new anti-tumor drug JND32066 was transferred to Guangzhou LiXin Pharmaceuticals for 100 million yuan, and another anti-tumor drug, JND30134, was transferred to Haihe Biopharma for 840 million yuan.